No Data
No Data
Xiangxue Pharmaceutical (300147.SZ): Xiangxue antiviral oral solution has the effects of clearing heat and dampness, cooling blood and detoxification.
On June 28th, Gelunhui reported that Xiangxue Pharmaceutical (300147.SZ) stated on the investor interactive platform that its Xiangxue Anti-Virus Oral Liquid has the functions of clearing hotness and dampness, cooling blood and detoxification, and is widely used clinically to treat diseases such as cold, flu, upper respiratory tract infection, and mumps virus.
Xiangxue Pharmaceutical (300147.SZ) has established traditional Chinese medicine production bases in Ningxia, Sichuan, Yunnan, Guangdong and other places.
On June 26th, Gelon Hui reported that Xiangxue Pharmaceutical (300147.SZ) develops, produces and sells modern traditional Chinese medicine and Chinese patent medicine. Its brand "Xiangxue" was awarded the China Famous Trademark. Its main products are famous brand products in Guangdong Province, which have a great influence in the southern and even national markets. The company has established Chinese herbal medicine production bases in Ningxia, Sichuan, Yunnan, Guangdong and other places, utilizing local abundant Chinese herbal medicine resources to establish processing bases and Chinese herbal medicine trading markets for the production, cultivation, harvesting, and processing of Chinese herbal medicine.
Xiangxue Pharmaceutical (300147.SZ): Xiangxue Anti-Virus Oral Liquid has the functions of clearing heat, removing dampness, cooling blood and detoxifying.
Xiangxue Pharmaceutical (300147.SZ) stated on the investor interaction platform that the company's chinese patent medicine main products include antiviral oral liquid, Juhong series (phlegm cough oral liquid, granule, decoction, pear paste), Banlangen granule, etc. Xiangxue antiviral oral liquid has the efficacy of clearing heat and dampness, cooling blood and detoxification. It is widely used in the treatment of diseases such as cold, flu, upper respiratory tract infection, mumps, viral conjunctivitis, and hand, foot and mouth disease. The company's Juhong phlegm cough liquid is heavily used in the precious traditional chinese medicine materials of Lingnan local name "Huajuhong", and is processed with bitter almond, white front, honey Hundred Department, Wuweizi to become "warm and transform cold phlegm".
Xiangxue Pharmaceutical (300147.SZ): Xiangxue Nanya intends to transfer assets of Deqing County Nanya Industrial Park project to Xingshun Agriculture for 88.04 million yuan.
Xiangxue Pharmaceutical (300147.SZ) announced on June 21 that, in order to further revitalize assets, improve asset liquidity and utilization efficiency, resolve debt disputes, its subsidiary Guangdong Xiangxue Southern Medicine Development Co., Ltd. (hereinafter referred to as "Xiangxue South Medicine" or "Party A") has signed an Asset Transfer Agreement for the Nanyao Industrial Park Project in Deqing County with Deqingyuan Management Bureau of Zhaoqing High-tech Zone (hereinafter referred to as "Party B") and Xingshun Agriculture Development Co., Ltd. of Deqing County (hereinafter referred to as "Xingshun Agriculture" or "Party C").
Analysis of BT Financial Report: Xiangxue Pharmaceutical's 2024 Q1 financial report: Challenges and Opportunities Coexist.
Xiangxue Pharmaceutical (stock code: 300147) is a company specializing in the research and production of traditional Chinese medicine, committed to promoting innovation and high-quality development of the traditional Chinese medicine industry. With the support of national policies, the company actively responds to the call of revitalizing and developing traditional Chinese medicine, constantly improves the quality management of traditional Chinese medicinal materials and the regulatory level of traditional Chinese medicine preparations. Xiangxue Pharmaceutical focuses on the innovation of traditional Chinese medicine research and development, optimizes the evaluation and approval mechanism of traditional Chinese medicine, improves the standard management level of traditional Chinese medicine, and actively participates in the globalization cooperation of traditional Chinese medicine regulation. Faced with the challenges of the pharmaceutical industry, the company strives to maintain competitiveness in the mark
Xiang Xue Pharmaceutical (300147.SZ): TCR-T and CAR-T are both adjuvant immune cell treatments
Gelonghui, May 11 | Xiangxue Pharmaceutical (300147.SZ) said on the interactive platform that TCR-T and CAR-T are both secondary immune cell treatments, that is, immune cells are isolated from cancer patients, genetically modified and amplified in vitro, and then transported back to the patient's body, but their mechanisms for recognizing antigens are quite different. CAR-T cells use antibody fragments that bind to specific antigens on the surface of cancer cells. TCR-T cells can recognize tumor-specific antigens from the surface of cell membranes or from within cells, and can target most tumor-specific antigens, especially those within tumor cells. So TC
No Data